Development of a new class of viral vectors “ Anellovectors “ with potential to deliver DNA payloads across broad tissue types in redosable manner Anellovectors demonstrate expanded payload capacity...
“ Publication describes the first gene delivery vector system based on a human commensal virus, the anellovirus “ “ Development of the Self-Amplifying Trans-complementation of a Universal Recombinant...
Translation of innate properties of anelloviruses to create Anellovectors with strengthened tropism and immune stealth, enabling redosability Transduction and expression across a variety of tissues...
Ring to present new data on its Anellogy„¢ platform The first new class of viral vector in decades - Robust transduction of a variety of cell and tissue types achieved by AnelloVectors Development of...
CAMBRIDGE, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today...
McNulty brings deep experience in capital formation and business development to Ring Follows recent appointment of Dr. Christopher Wright as Chief Medical Officer CAMBRIDGE, Mass., May 01, 2023 ...
Ring Therapeutics Raises $86.5 Million in Series C Funding to Create Next Generation Programmable Medicines
Ring Therapeutics Announces Appointment of Industry Veteran Christopher Wright, M.D., Ph.D. as Chief Medical Officer, Head of Translational Research
CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today announced the issuance of U.S. Patent No. 11,446,344. The patent, which was granted to Flagship Pioneering, is exclusively licensed to Ring Therapeutics.
CAMBRIDGE, Mass., July 18, 2022 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize gene therapy with its commensal virome platform, today...